Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 346,601,664
  • Shares Outstanding, K 2,639,166
  • Annual Sales, $ 81,581 M
  • Annual Income, $ 15,297 M
  • 60-Month Beta 0.69
  • Price/Sales 4.18
  • Price/Cash Flow 11.84
  • Price/Book 5.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 2.00
  • Number of Estimates 7
  • High Estimate 2.02
  • Low Estimate 1.98
  • Prior Year 2.05
  • Growth Rate Est. (year over year) -2.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
126.70 +3.48%
on 09/27/19
134.70 -2.67%
on 10/02/19
+0.33 (+0.25%)
since 09/13/19
3-Month
126.34 +3.78%
on 09/10/19
136.36 -3.85%
on 07/15/19
-3.19 (-2.38%)
since 07/12/19
52-Week
121.00 +8.36%
on 12/24/18
148.99 -12.00%
on 12/04/18
-2.76 (-2.06%)
since 10/12/18

Most Recent Stories

More News
U.S. FDA Approves XARELTO® (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban) for the prevention of venous thromboembolism...

JNJ : 130.69 (-0.49%)
Latest Innovations in Medical Device Technologies, 2017-2019 & 2023 - Major Players are Abbott Laboratories, Boston Scientific, General Electric Co, Johnson & Johnson, and Paradromics

The "Latest Innovations in Medical Device Technologies" report has been added to ResearchAndMarkets.com's offering.

BSX : 38.41 (+0.47%)
GE : 8.66 (-1.59%)
JNJ : 130.69 (-0.49%)
MEDD : 0.0030 (-58.90%)
What to Expect from Q3 Earnings Season with Big Banks Set to Report?

What to Expect from Q3 Earnings Season with Big Banks Set to Report?

WFC : 49.17 (-0.08%)
SLB : 31.94 (-1.66%)
PNC : 139.79 (-0.43%)
NFLX : 285.58 (+0.94%)
MU : 45.20 (+0.22%)
JPM : 115.94 (-0.17%)
JNJ : 130.69 (-0.49%)
IBM : 142.28 (-0.34%)
GS : 204.37 (-0.15%)
BAC : 28.79 (-0.42%)
AAPL : 235.75 (-0.19%)
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals

FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.

LLY : 108.27 (-0.08%)
PFE : 36.16 (+0.14%)
NVO : 52.03 (+1.56%)
BMY : 51.56 (-0.10%)
NVS : 85.73 (-1.00%)
JNJ : 130.69 (-0.49%)
GSK : 42.38 (+0.47%)
Will Q3 Earnings Drive Dow ETF Higher?

With most blue-chip companies earnings scheduled over the coming weeks and sentiments being mixed, investors should closely monitor the movement of the Dow ETF and grab an opportunity that arises from...

IBM : 142.28 (-0.34%)
JPM : 115.94 (-0.17%)
JNJ : 130.69 (-0.49%)
MSFT : 140.17 (+0.35%)
GS : 204.37 (-0.15%)
DIA : 267.81 (-0.13%)
UNH : 222.61 (+0.24%)
Geron Starts Enrollment in Phase III MDS Study on Imetelstat

Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.

JNJ : 130.69 (-0.49%)
XLRN : 39.47 (+2.87%)
CELG : 100.57 (+0.76%)
GERN : 1.51 (-1.31%)
Fred Moll Named Chairman of the Board at MIVI Neuroscience

MIVI Neuroscience, Inc. today announced the appointment of Fred Moll, MD as Chairman of its Board of Directors.

HNSN : 3.99 (unch)
ISRG : 521.48 (+0.67%)
JNJ : 130.69 (-0.49%)
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.

LLY : 108.27 (-0.08%)
ABBV : 73.60 (-0.04%)
PFE : 36.16 (+0.14%)
JNJ : 130.69 (-0.49%)
Company News For Oct 10, 2019

Companies in the news are: JNJ, X, TGT, OCGN

JNJ : 130.69 (-0.49%)
TGT : 111.79 (-0.04%)
X : 11.14 (-1.76%)
OCGN : 1.50 (-1.96%)
Point of Care (POC) Diagnostics Market Review and Outlook 2017-2023 - Leading Players are Roche, Johnson & Johnson, Alere, Abbott, Siemens, and Danaher

The "Point of Care Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

JNJ : 130.69 (-0.49%)
SIEGY : 54.6700 (+2.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 133.39
1st Resistance Point 132.36
Last Price 130.96
1st Support Level 130.56
2nd Support Level 129.79

See More

52-Week High 148.99
Fibonacci 61.8% 138.30
Fibonacci 50% 134.99
Fibonacci 38.2% 131.69
Last Price 130.96
52-Week Low 121.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar